Abstract

The present invention relates to CGRP antagonists of general formula

5

$$\begin{array}{c} V \\ V \\ R^2 \\ N \\ R^3 \\ \end{array}, (I)$$

wherein A, U, V, W, X and R¹ to R³ are defined as in claim 1,

the tautomers, diastereomers, enantiomers, hydrates, mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them.